查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1445540

全球前列腺癌活检市场评估：按产品类型、指南、最终用户和地区划分的机会和预测（2017-2031）

Prostate Cancer Biopsy Market Assessment, By Type, By Product, By Guidance, By End-user, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 225 Pages | 商品交期: 3-5个工作天内

价格

全球前列腺癌活检市场规模将从 2023 年的 60.9 亿美元增长到 2031 年的 110.6 亿美元，2024-2031 年预测期内复合年增长率为 7.74%。预计将增长至 .

影响全球前列腺癌活检市场的因素包括使用人工智慧工具进行前列腺癌活检、政府举措、对试剂盒的需求不断增加、前列腺液体活检日益普及、MRI 引导等。其中包括采用更安全的导引设备。

全球前列腺癌活检市场受到几个关键因素的影响，这些因素反映了不断发展的医疗技术和不断发展的医疗保健实践。 提高癌症识别准确性和有效性的一项显着进展是在前列腺癌活检中使用人工智慧技术。 人工智慧系统可以准确分析切片影像，改善患者治疗结果，并减少误诊机会。

透过使用人工智慧工具增加需求

全球前列腺癌切片的销售急剧成长，这主要归功于技术进步，尤其是人工智慧技术的使用。 这些人工智慧技术透过提高活检过程的准确性和一致性，正在彻底改变前列腺癌的诊断。 人工智慧系统能够分析复杂的活检影像并侦测人眼可能错过的模式和讯号。

透过减少假阴性的机会并提高恶性细胞的检出率，患者可以得到准确的早期诊断。 将人工智慧纳入前列腺癌活检程序代表了肿瘤学的重大进步，并将改善全球前列腺癌人口数量，因为它可以提供更有效、更准确、侵入性更小的方法来识别前列腺癌。这有望刺激增长和创新在检验市场。

政府措施

世界各国政府正在积极推动前列腺癌宣传活动和筛检计划，这为全球前列腺癌活检市场的成长提供了重要推动力。 这些计划对于早期发现、提高治疗效果和生存机会至关重要。 各国政府支持和促进前列腺癌筛检计划，鼓励男性接受活检等早期诊断测试。 透过使更多的人在疾病的早期阶段得到诊断和治疗，这些措施将有助于降低与前列腺癌相关的死亡率，并刺激全球前列腺癌活检市场。

套件需求增加

对活检试剂盒的需求不断增长是全球前列腺癌活检市场显着增长的原因。 这些试剂盒在诊断前列腺癌所需的活检中发挥重要作用。 向微创诊断技术的转变可提高便利性、患者舒适度和依从性，从而导致需求增加。 活检套件简化了医疗保健专业人员的流程，并确保成功、快速地进行活检。

摄护腺液体切片检查日益普及

前列腺液体活检在全球前列腺癌活检市场中越来越受欢迎，代表着向非侵入性诊断技术的重大转变。 透过分析患者血液中的循环肿瘤细胞和肿瘤 DNA 片段，液体活检提供了比标准组织活检侵入性更小的选择。 液体活检正在广泛接受，因为它们可以早期发现癌症、追踪其进展并评估治疗效果。

本报告调查了全球前列腺癌活检市场，提供市场定义和概述、市场规模趋势和预测、各个细分市场和地区的详细分析、行业结构以及影响市场成长的因素。分析、案例研究、竞争格局、以及主要公司的简介。

目录

第 1 章研究方法

第 2 章专案范围与定义

第 3 章执行摘要

第 4 章全球前列腺癌切片市场展望

  • 市场规模/预测
  • 依类型
    • 前列腺液体活检
    • 前列腺穿刺活检
  • 按产品
    • 针
    • 套件托盘
    • 其他
  • 透过指导
    • MRI引导的摄护腺切片装置
    • CT引导摄护腺切片装置
    • 超音波引导摄护腺切片装置
    • 其他
  • 按最终用户
    • 医院
    • 诊断中心
    • 其他
  • 按地区
    • 北美
    • 欧洲
    • 亚太地区
    • 南美洲
    • 中东/非洲
  • 各公司的市占率

第 5 章全球前列腺癌切片市场展望：按地区

  • 北美
  • 欧洲
  • 亚太地区
  • 南美洲
  • 中东/非洲

第 6 章市场映射

  • 依类型
  • 按产品
  • 透过指导
  • 按最终用户
  • 按地区

第 7 章宏观环境与产业结构

  • 需求与供给分析
  • 汇入/汇出分析
  • 价值链分析
  • PESTEL 分析
  • 波特五力分析

第 8 章市场动态

  • 生长促进因素
  • 生长抑制因素（问题、限制因素）

第 9 章监理架构与创新

  • 临床试验
  • 专利情况
  • 监理机关的核准
  • 创新/新兴技术

第 10 章主要公司状况

  • 前 5 名市场领导者的竞争矩阵
  • 前 5 位市场领导者的市场收入分析
  • 併购/合资企业（如果适用）
  • SWOT 分析（5 家参与公司）
  • 专利分析（如果适用）

第 11 章价格分析

第 12 章案例研究

第 13 章主要公司展望

  • Thermo Fisher Scientific Inc.
  • Becton Dickinson and Company
  • F. Hoffmann-La Roche Ltd.
  • AstraZeneca plc
  • Koninklijke Philips N.V.
  • Biocept Inc
  • Angle plc
  • Eisai Co., Ltd.
  • Onconetix, Inc.
  • StageZero Life Sciences Ltd

第 14 章策略建议

第 15 章关于我们公司/免责声明

Product Code: MX11089

Global prostate cancer biopsy market is projected to witness a CAGR of 7.74% during the forecast period 2024-2031, growing from USD 6.09 billion in 2023 to USD 11.06 billion in 2031. Factors that shape the global prostate cancer biopsy market include the use of AI tools for prostate cancer biopsies, government initiatives, increased demand for kits, the growing popularity of prostate liquid biopsy and the adoption of safer guidance devices such as MRI-guidance.

The global prostate cancer biopsy market is influenced by several important factors, which are the reflection of evolving medical technology and evolving healthcare practices. One notable development that improves the accuracy and effectiveness of cancer identification is the use of AI techniques in prostate cancer biopsies. AI systems can accurately analyze biopsy images, improving patient outcomes and reducing the likelihood of a misdiagnosis.

In the global prostate cancer biopsy market, government initiatives that provide funding and assistance for developments in cancer diagnosis are crucial to the progress of the field's research and development. The two main objectives of these projects are raising awareness and improving accessibility of enhanced diagnostic instruments.

Additionally, the growing incidence of prostate cancer is driving the demand for biopsy kits, which in turn is propelling the growth of the global prostate cancer biopsy market. These kits make the biopsy process more patient-friendly by enabling less intrusive treatments and providing convenience. Another development is the increasing prevalence of liquid biopsies of the prostate. By analyzing cancer cell DNA in the blood, liquid biopsies provide a non-invasive substitute for traditional tissue biopsies while providing vital tumor information.

Consequently, the precision of biopsies has increased with the use of safer guidance tools, including MRI-guided biopsy devices. With improved visualization of prostate gland made possible by MRI guidance, suspicious regions can be sampled more precisely, reducing biopsy risks. Together, these elements influence the dynamics of the global prostate cancer biopsy market for prostate cancer biopsies, suggesting ways to enhance patient care and diagnostic options.

Philips and imaging biomarker specialist Quibim partnered in October 2023 to introduce the next generation of AI-based imaging and reporting solutions for MR prostate exams. Combining Quibim's AI-enabled image analysis software with Philips' allows physicians to treat prostate cancer patients more quickly and effectively while reducing costs and staffing shortages.

Use of AI Tools to Expand the Demand

Prostate cancer biopsy sales are rising dramatically worldwide, mostly because of advances in technology, especially the use of AI techniques. These artificial intelligence technologies are improving the accuracy and consistency of biopsy processes, which is revolutionizing the diagnosis of prostate cancer. Artificial intelligence systems possess the ability to analyze intricate biopsy images and detect patterns and signals which human eye would overlook.

Reducing the possibility of false negative results and raising the detection rate of malignant cells guarantees that patients obtain accurate and early diagnoses. By providing a more effective, precise, and minimally invasive method of identifying prostate cancer, the incorporation of AI into prostate cancer biopsy procedures marks a significant advancement in oncology and spurs growth and innovation in the global prostate cancer biopsy market.

For instance, a Florida-based medical technology company introduced a cutting-edge AI diagnostic for prostate cancer treatment in April 2023. Doctors are assisted in selecting individualized patient care by ArteraAI's "first-ever predictive test." Patients with localized prostate cancer benefit from being the first of its kind.

Government Initiatives

Prostate cancer awareness campaigns and screening programs are actively promoted by governments across the globe, which has greatly fueled the expansion of the global prostate cancer biopsy market. These programs are essential for early detection and enhance the effectiveness of treatment and their likelihood of survival. Governments encourage men to undergo early diagnostic tests, such as biopsies, by supporting and promoting prostate cancer screening programs. It increases the demand for biopsy procedures and related technology. By ensuring that more people are diagnosed and treated in the early stages of the disease, such initiatives contribute to lowering the death rate related to prostate cancer and stimulate the global prostate cancer biopsy market.

For instance, on 19th November 2023, The United Kingdom Government initiated a significant prostate cancer screening experiment. A screening trial was announced by Prostate Cancer UK and the Government to find ways to diagnose prostate cancer proactively. Thousands of men who are more likely to get cancer were recruited by them. The trial, named TRANSFORM, will use innovative techniques such as magnetic resonance imaging (MRI) screening to discover cases not detected by blood testing and in the absence of cancer symptoms.

Increased Demand for Kits

The growing need for biopsy kits is behind the significant expansion of global prostate cancer biopsy market. These kits play a crucial role in biopsies, which are necessary for the diagnosis of prostate cancer. Their convenience and the move to less invasive diagnostic techniques, which improve patient comfort and compliance, are credited with their increased demand. Biopsy kits facilitate the process for medical professionals, guaranteeing the successful and rapid execution of biopsies. The pattern is part of a larger shift in healthcare that is patient-centric and emphasizes reducing discomfort and increasing diagnostic precision. The global prostate cancer biopsy market is expected to grow significantly as the awareness and prevalence of prostate cancer increase, leading to a rise in demand for these kits.

Co-labeled digital PCR kits are marketed by Stilla Technologies and Atila Biosystems started in March 2023. "naica" is Stilla's primary PCR device, and the kits and assays are made by Atila. The purpose of these digital PCR kits is to identify circulating tumor DNA (ctDNA) in liquid biopsy samples. These samples are obtained from patients with prostate, colon, melanoma, lung, and breast cancer.

Growing Popularity of Prostate Liquid Biopsy

Prostate liquid biopsies are becoming increasingly common in the global prostate cancer biopsy market, which represents a significant shift towards non-invasive diagnostic techniques. Liquid biopsies provide a less invasive option than standard tissue biopsies by analyzing circulating tumor cells or bits of tumor DNA in a patient's blood. The approach is a desirable choice for patients and healthcare professionals because it greatly lowers patient suffering and the chance of problems. Liquid biopsies are becoming more widely accepted due to their ability to detect cancer early, track its course, and evaluate the effectiveness of treatment. The trend highlights the increasing need for better patient-friendly, precise, and effective diagnostic technologies in the management of prostate cancer, which is driving innovation in the global prostate cancer biopsy market.

PanGIA Biotech announced in January 2024 that it aims to develop scalable and real liquid biopsy technology for global impact. It has completed its prospective, multicenter, three-year clinical study on liquid biopsy for prostate cancer and the study was conducted prospectively. The news was announced as the business got ready to start more clinical trials with the PanGIA Liquid Biopsy Platform for early multi-cancer diagnosis.

North America Dominates the Market

The global prostate cancer biopsy market is dominated by North America, which is a result of several important factors. Firstly, the area is home to a highly developed healthcare infrastructure with a focus on cancer research and diagnostics, which is made possible by significant expenditure on medical technology. The population's high level of knowledge of prostate cancer and the value of early detection plays a significant role in the high demand for biopsy procedures.

Also, the strong regulatory environment and pro-innovation policies in healthcare in North America aid in the quick uptake of cutting-edge diagnostic tools like AI-enhanced imaging and MRI-guided biopsies. When assessed together, these factors guarantee North America's dominant position in the industry, propelling advancement and establishing global benchmarks for prostate cancer diagnosis.

Oxford BioDynamics, plc announced in September 2023 that its EpiSwitch Prostate Screening (PSE) blood test has been validated in its US clinical laboratory. It means men who are at risk of prostate cancer can immediately access their highly accurate PSE test.

Future Market Scenario (2024 - 2031F)

The global prostate cancer biopsy market is expected to be significantly impacted by the excessive adoption of AI tools. The market is to be benefited from the increasing accessibility of the technology in the future.

The rising demand for minimally invasive procedures, such as liquid biopsies, will significantly propel the growth of the market in the future. Liquid biopsy requires less time and delivers precise results.

The need for biopsy techniques and diagnostic technology may rise significantly in various countries in Asia, Africa, and Latin America due to rising access to healthcare facilities and upgrading healthcare infrastructure. The growth will positively impact the global prostate cancer biopsy market in the future.

Healthcare professionals are actively adopting numerous screening techniques like active surveillance and tailored screening which will boost the growth of the global prostate cancer biopsy market in the future.

Key Players Landscape and Outlook

Major firms in the global prostate cancer biopsy market are engaging in collaborations. It is a strategy that greatly boosts growth and innovation in the global prostate cancer biopsy market. Companies can make use of each other's advantages through these collaborations, which frequently involve sharing technology breakthroughs, research capacity, and market access. Partnerships may result in the creation of less intrusive, more precise biopsy technologies, improving patient care and diagnostic accuracy. To increase detection rates, technology businesses and biopharmaceutical companies should form partnerships to expedite the integration of AI and machine learning in biopsy analysis. In addition to advancing technology, these joint initiatives broaden the application of cutting-edge diagnostic tools and provide a cooperative yet competitive market environment that benefits patients everywhere.

Following the successful evaluation of a blood-based genomic profiling test in prostate cancer, MBdx and AstraZeneca extended their collaboration agreement in June 2023 to support the shift from tissue to liquid biopsy. With the help of the PROSPER 2.0 project's AlphaLiquid HRR test, patients with metastatic castration-resistant prostate cancer (mCRPC) now have a plethora of options.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Prostate Cancer Biopsy Market Outlook, 2017-2031F

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
    • 4.1.2. By Volume
  • 4.2. By Type
    • 4.2.1. Prostate Liquid Biopsy
    • 4.2.2. Prostate Needle Biopsy
  • 4.3. By Product
    • 4.3.1. Needles
    • 4.3.2. Kits and Trays
    • 4.3.3. Others
  • 4.4. By Guidance
    • 4.4.1. MRI-Guided Prostate Biopsy Devices
    • 4.4.2. CT-Guided Prostate Biopsy Devices
    • 4.4.3. Ultrasound-Guided Prostate Biopsy Devices
    • 4.4.4. Others
  • 4.5. By End-user
    • 4.5.1. Hospitals
    • 4.5.2. Diagnostic Centers
    • 4.5.3. Others
  • 4.6. By Region
    • 4.6.1. North America
    • 4.6.2. Europe
    • 4.6.3. Asia-Pacific
    • 4.6.4. South America
    • 4.6.5. Middle East and Africa
  • 4.7. By Company Market Share (%), 2023

5. Global Prostate Cancer Biopsy Market Outlook, By Region, 2017-2031F

  • 5.1. North America*
    • 5.1.1. Market Size & Forecast
      • 5.1.1.1. By Value
      • 5.1.1.2. By Volume
    • 5.1.2. By Type
      • 5.1.2.1. Prostate Liquid Biopsy
      • 5.1.2.2. Prostate Needle Biopsy
    • 5.1.3. By Product
      • 5.1.3.1. Needles
      • 5.1.3.2. Kits and Trays
      • 5.1.3.3. Others
    • 5.1.4. By Guidance
      • 5.1.4.1. MRI-Guided Prostate Biopsy Devices
      • 5.1.4.2. CT-Guided Prostate Biopsy Devices
      • 5.1.4.3. Ultrasound-Guided Prostate Biopsy Devices
      • 5.1.4.4. Others
    • 5.1.5. By End-user
      • 5.1.5.1. Hospitals
      • 5.1.5.2. Diagnostic Centers
      • 5.1.5.3. Others
    • 5.1.6. United States*
      • 5.1.6.1. Market Size & Forecast
      • 5.1.6.1.1. By Value
      • 5.1.6.1.2. By Volume
      • 5.1.6.2. By Type
      • 5.1.6.2.1. Prostate Liquid Biopsy
      • 5.1.6.2.2. Prostate Needle Biopsy
      • 5.1.6.3. By Product
      • 5.1.6.3.1. Needles
      • 5.1.6.3.2. Kits and Trays
      • 5.1.6.3.3. Others
      • 5.1.6.4. By Guidance
      • 5.1.6.4.1. MRI-Guided Prostate Biopsy Devices
      • 5.1.6.4.2. CT-Guided Prostate Biopsy Devices
      • 5.1.6.4.3. Ultrasound-Guided Prostate Biopsy Devices
      • 5.1.6.4.4. Others
      • 5.1.6.5. By End-user
      • 5.1.6.5.1. Hospitals
      • 5.1.6.5.2. Diagnostic Centers
      • 5.1.6.5.3. Others
    • 5.1.7. Canada
    • 5.1.8. Mexico

All segments will be provided for all regions and countries covered

  • 5.2. Europe
    • 5.2.1. Germany
    • 5.2.2. France
    • 5.2.3. Italy
    • 5.2.4. United Kingdom
    • 5.2.5. Russia
    • 5.2.6. Netherlands
    • 5.2.7. Spain
    • 5.2.8. Turkey
    • 5.2.9. Poland
  • 5.3. Asia-Pacific
    • 5.3.1. India
    • 5.3.2. China
    • 5.3.3. Japan
    • 5.3.4. Australia
    • 5.3.5. Vietnam
    • 5.3.6. South Korea
    • 5.3.7. Indonesia
    • 5.3.8. Philippines
  • 5.4. South America
    • 5.4.1. Brazil
    • 5.4.2. Argentina
  • 5.5. Middle East & Africa
    • 5.5.1. Saudi Arabia
    • 5.5.2. UAE
    • 5.5.3. South Africa

6. Market Mapping, 2023

  • 6.1. By Type
  • 6.2. By Product
  • 6.3. By Guidance
  • 6.4. By End-user
  • 6.5. By Region

7. Macro Environment and Industry Structure

  • 7.1. Demand Supply Analysis
  • 7.2. Import Export Analysis
  • 7.3. Value Chain Analysis
  • 7.4. PESTEL Analysis
    • 7.4.1. Political Factors
    • 7.4.2. Economic System
    • 7.4.3. Social Implications
    • 7.4.4. Technological Advancements
    • 7.4.5. Environmental Impacts
    • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5. Porter's Five Forces Analysis
    • 7.5.1. Supplier Power
    • 7.5.2. Buyer Power
    • 7.5.3. Substitution Threat
    • 7.5.4. Threat from New Entrant
    • 7.5.5. Competitive Rivalry

8. Market Dynamics

  • 8.1. Growth Drivers
  • 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

  • 9.1. Clinical Trials
  • 9.2. Patent Landscape
  • 9.3. Regulatory Approvals
  • 9.4. Innovations/Emerging Technologies

10. Key Players Landscape

  • 10.1. Competition Matrix of Top Five Market Leaders
  • 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4. SWOT Analysis (For Five Market Players)
  • 10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

  • 13.1. Thermo Fisher Scientific Inc.
    • 13.1.1. Company Details
    • 13.1.2. Key Management Personnel
    • 13.1.3. Products & Services
    • 13.1.4. Financials (As reported)
    • 13.1.5. Key Market Focus & Geographical Presence
    • 13.1.6. Recent Developments
  • 13.2. Becton Dickinson and Company
  • 13.3. F. Hoffmann-La Roche Ltd.
  • 13.4. AstraZeneca plc
  • 13.5. Koninklijke Philips N.V.
  • 13.6. Biocept Inc
  • 13.7. Angle plc
  • 13.8. Eisai Co., Ltd.
  • 13.9. Onconetix, Inc.
  • 13.10. StageZero Life Sciences Ltd

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14. Strategic Recommendations

15. About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 3. Global Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 4. Global Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 5. Global Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 6. Global Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 7. Global Prostate Cancer Biopsy Market Share (%), By Region, 2017-2031F
  • Figure 8. North America Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 9. North America Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 10. North America Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 11. North America Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 12. North America Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 13. North America Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 14. North America Prostate Cancer Biopsy Market Share (%), By Country, 2017-2031F
  • Figure 15. United States Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 16. United States Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 17. United States Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 18. United States Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 19. United States Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 20. United States Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 21. Canada Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 22. Canada Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 23. Canada Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 24. Canada Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 25. Canada Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 26. Canada Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 27. Mexico Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 28. Mexico Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 29. Mexico Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 30. Mexico Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 31. Mexico Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 32. Mexico Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 33. Europe Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 34. Europe Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 35. Europe Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 36. Europe Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 37. Europe Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 38. Europe Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 39. Europe Prostate Cancer Biopsy Market Share (%), By Country, 2017-2031F
  • Figure 40. Germany Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 41. Germany Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 42. Germany Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 43. Germany Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 44. Germany Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 45. Germany Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 46. France Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 47. France Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 48. France Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 49. France Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 50. France Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 51. France Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 52. Italy Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 53. Italy Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 54. Italy Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 55. Italy Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 56. Italy Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 57. Italy Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 58. United Kingdom Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 59. United Kingdom Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 60. United Kingdom Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 61. United Kingdom Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 62. United Kingdom Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 63. United Kingdom Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 64. Russia Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 65. Russia Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 66. Russia Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 67. Russia Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 68. Russia Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 69. Russia Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 70. Netherlands Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 71. Netherlands Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 72. Netherlands Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 73. Netherlands Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 74. Netherlands Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 75. Netherlands Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 76. Spain Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 77. Spain Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 78. Spain Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 79. Spain Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 80. Spain Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 81. Spain Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 82. Turkey Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 83. Turkey Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 84. Turkey Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 85. Turkey Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 86. Turkey Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 87. Turkey Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 88. Poland Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 89. Poland Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 90. Poland Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 91. Poland Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 92. Poland Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 93. Poland Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 94. South America Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 95. South America Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 96. South America Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 97. South America Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 98. South America Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 99. South America Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 100. South America Prostate Cancer Biopsy Market Share (%), By Country, 2017-2031F
  • Figure 101. Brazil Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 102. Brazil Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 103. Brazil Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 104. Brazil Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 105. Brazil Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 106. Brazil Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 107. Argentina Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 108. Argentina Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 109. Argentina Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 110. Argentina Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 111. Argentina Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 112. Argentina Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 113. Asia-Pacific Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 114. Asia-Pacific Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 115. Asia-Pacific Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 116. Asia-Pacific Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 117. Asia-Pacific Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 118. Asia-Pacific Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 119. Asia-Pacific Prostate Cancer Biopsy Market Share (%), By Country, 2017-2031F
  • Figure 120. India Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 121. India Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 122. India Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 123. India Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 124. India Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 125. India Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 126. China Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 127. China Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 128. China Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 129. China Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 130. China Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 131. China Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 132. Japan Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 133. Japan Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 134. Japan Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 135. Japan Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 136. Japan Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 137. Japan Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 138. Australia Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 139. Australia Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 140. Australia Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 141. Australia Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 142. Australia Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 143. Australia Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 144. Vietnam Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 145. Vietnam Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 146. Vietnam Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 147. Vietnam Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 148. Vietnam Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 149. Vietnam Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 150. South Korea Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 151. South Korea Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 152. South Korea Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 153. South Korea Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 154. South Korea Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 155. South Korea Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 156. Indonesia Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 157. Indonesia Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 158. Indonesia Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 159. Indonesia Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 160. Indonesia Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 161. Indonesia Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 162. Philippines Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 163. Philippines Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 164. Philippines Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 165. Philippines Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 166. Philippines Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 167. Philippines Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 168. Middle East & Africa Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 169. Middle East & Africa Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 170. Middle East & Africa Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 171. Middle East & Africa Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 172. Middle East & Africa Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 173. Middle East & Africa Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 174. Middle East & Africa Prostate Cancer Biopsy Market Share (%), By Country, 2017-2031F
  • Figure 175. Saudi Arabia Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 176. Saudi Arabia Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 177. Saudi Arabia Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 178. Saudi Arabia Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 179. Saudi Arabia Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 180. Saudi Arabia Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 181. UAE Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 182. UAE Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 183. UAE Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 184. UAE Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 185. UAE Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 186. UAE Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 187. South Africa Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 188. South Africa Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 189. South Africa Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 190. South Africa Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 191. South Africa Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 192. South Africa Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 193. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 194. By Product Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 195. By Guidance Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 196. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 197. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023